Breaking News, Collaborations & Alliances

Lupin, Salix Expand Rifaximin Pact

Lupin Ltd. has granted Salix Pharmaceuticals, Ltd. exclusive worldwide rights (except for India) to use Lupin technology for all rifaximin products for human use.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lupin Ltd. has granted Salix Pharmaceuticals, Ltd. exclusive worldwide rights (except for India) to use Lupin technology for all rifaximin products for human use. This agreement expands the companies’ collaboration dating back to September 2009. Under the expanded agreement Lupin will supply Salix with rifaximin API and certain finished rifaximin products. Lupin will receive a $10 million up-front payment as well as potential U.S. regulatory milestones for products covered by Lupin patents or...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters